Phase 1 T-cell Lymphoma Clinical Trials
35 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 35 trials
Recruiting
Phase 1Phase 2
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Recurrent Mycosis FungoidesRefractory Mycosis FungoidesSezary Syndrome+5 more
City of Hope Medical Center78 enrolled4 locationsNCT03011814
Recruiting
Phase 1Phase 2
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Aggressive NK-cell LeukemiaLGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell Lymphoma+10 more
Dren Bio200 enrolled37 locationsNCT05475925
Recruiting
Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting
Phase 1
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Classical Hodgkin LymphomaExtranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Baylor College of Medicine18 enrolled2 locationsNCT04288726
Recruiting
Phase 1
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedMature T-Cell and NK-Cell Non-Hodgkin LymphomaFollicular Helper T-Cell Lymphoma+3 more
City of Hope Medical Center20 enrolled1 locationNCT07278856
Recruiting
Phase 1
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting
Phase 1Phase 2
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Hodgkin LymphomaNon-Hodgkin LymphomaLymphoma+4 more
AstraZeneca161 enrolled35 locationsNCT06137144
Recruiting
Phase 1Phase 2
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
T-cell LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPTCL
Peking University People's Hospital30 enrolled1 locationNCT06874946
Recruiting
Phase 1
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory T-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University25 enrolled1 locationNCT06696846
Recruiting
Phase 1
CD4CAR for CD4+ Leukemia and Lymphoma
T-cell LymphomaT-cell Leukemia
Huda Salman20 enrolled6 locationsNCT03829540
Recruiting
Phase 1Phase 2
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
T-cell Lymphomas
Dizal Pharmaceuticals165 enrolled12 locationsNCT07496229
Recruiting
Phase 1
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
T-cell Prolymphocytic LeukemiaT-cell LymphomasNK-Cell Lymphomas+1 more
Memorial Sloan Kettering Cancer Center70 enrolled9 locationsNCT05010005
Recruiting
Phase 1
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
T-cell LymphomaAnaplastic Large Cell LymphomaAdult T-cell Leukemia/Lymphoma+3 more
National Cancer Institute (NCI)20 enrolled1 locationNCT07388563
Recruiting
Phase 1
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Refractory/Recurrent Peripheral T-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University45 enrolled1 locationNCT07164560
Recruiting
Phase 1
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
T-cell Acute Lymphoblastic LeukemiaLymphoblastic T-Cell Lymphoma
OneChain Immunotherapeutics20 enrolled2 locationsNCT05679895
Recruiting
Phase 1Phase 2
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Ovarian CancerMelanomaT-cell Lymphoma+1 more
BioInvent International AB176 enrolled25 locationsNCT04752826
Recruiting
Phase 1
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.255 enrolled17 locationsNCT06393738
Recruiting
Phase 1Phase 2
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Haihe Biopharma Co., Ltd.100 enrolled1 locationNCT06909877
Recruiting
Phase 1
Q702 for the Treatment of Patients With Hematologic Malignancies
Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810